Tenpoint Therapeutics and PHIL Collaborate to Introduce YUVEZZI™ Direct-to-Patient Cash Program, Improving Access and Affordability for Presbyopia Care
Tenpoint Therapeutics, a company focused on advancing innovative treatments in eye care, has partnered with PHIL Inc. to introduce a new Direct-to-Patient (DTP) cash program for YUVEZZI. This initiative represents a significant step forward in improving access to prescription therapies for patients living with Presbyopia, a highly prevalent age-related vision disorder.
YUVEZZI is notable as the first and only dual-agent prescription eye drop approved by the U.S. Food and Drug Administration for the treatment of presbyopia. The condition, which typically begins to affect individuals in their 40s and progresses with age, results in the gradual loss of the eye’s ability to focus on nearby objects. Despite its widespread nature—impacting approximately 128 million people in the United States and an estimated 2 billion globally—presbyopia remains significantly undertreated. Many patients rely on over-the-counter solutions such as reading glasses rather than seeking prescription therapies, often due to cost concerns, limited awareness, and complex access pathways.
The newly launched DTP program is designed to address these longstanding barriers by simplifying the patient journey and providing a more accessible route to treatment. Traditional pharmaceutical distribution models can involve multiple intermediaries, including pharmacies, insurers, and healthcare providers, which can create delays, increase costs, and reduce adherence. By contrast, the direct-to-patient approach allows eligible patients to obtain YUVEZZI more efficiently, with transparent pricing and home delivery services that eliminate many of the logistical challenges associated with conventional access models.
At the core of this initiative is the integration of PHIL Inc.’s digital health platform, which serves as an all-in-one hub for prescription management, patient engagement, and medication fulfillment. Through this platform, patients can navigate the process of obtaining YUVEZZI in a streamlined and user-friendly manner. The system is designed to support not only initial access but also ongoing adherence, which is critical for achieving optimal treatment outcomes in chronic conditions such as presbyopia.
One of the key advantages of the DTP program is its focus on affordability. High out-of-pocket costs have historically been a major deterrent for patients considering prescription treatments for presbyopia. By offering a cash-based model with clear and predictable pricing, the program aims to reduce financial uncertainty and make the therapy more accessible to a broader population. This approach aligns with a growing trend in the healthcare industry toward pricing transparency and patient-centered care.
In addition to affordability, the program emphasizes convenience and support. Patients enrolled in the DTP program will benefit from direct home delivery of YUVEZZI, eliminating the need for pharmacy visits and reducing the time required to begin treatment. The program also includes dedicated support services to assist patients throughout their treatment journey, addressing questions, providing guidance, and helping to ensure consistent use of the therapy.
The partnership between Tenpoint Therapeutics and PHIL Inc. reflects a shared commitment to reimagining how patients access and experience healthcare. By leveraging digital technology and innovative distribution models, the two companies aim to create a more seamless and patient-centric approach to treatment delivery. This is particularly important in ophthalmology, where adherence to therapy can be influenced by factors such as ease of use, accessibility, and patient education.
Deepak Thomas, CEO and founder of PHIL Inc., highlighted the significance of the collaboration, noting that the launch of YUVEZZI through a direct-to-patient program represents a meaningful advancement for individuals living with presbyopia. He emphasized that the initiative demonstrates the potential of prioritizing patient access and underscores the importance of removing barriers that have historically limited the adoption of effective therapies.
From a broader perspective, the introduction of this DTP program signals a shift in how pharmaceutical companies are approaching patient engagement and access. As healthcare systems evolve, there is increasing recognition of the need to design solutions that align with patients’ preferences and lifestyles. Direct-to-patient models, supported by digital platforms, offer a promising avenue for achieving this goal by delivering therapies in a way that is both convenient and cost-effective.
The launch of YUVEZZI’s DTP program also highlights the growing role of innovation in addressing unmet medical needs. While presbyopia is not a life-threatening condition, it can significantly impact quality of life, affecting daily activities such as reading, using digital devices, and performing close-up tasks. By providing a novel treatment option that is both effective and accessible, Tenpoint Therapeutics and PHIL Inc. are helping to improve the standard of care for millions of patients.
Furthermore, the program has the potential to serve as a model for other therapeutic areas where access and adherence challenges persist. By demonstrating the benefits of a direct-to-patient approach, this initiative may encourage broader adoption of similar models across the healthcare industry, ultimately contributing to more efficient and patient-centered care delivery.
In conclusion, the launch of the Direct-to-Patient cash program for YUVEZZI marks an important milestone in the evolution of presbyopia treatment. Through their collaboration, Tenpoint Therapeutics and PHIL Inc. are addressing key barriers to access, including cost, complexity, and convenience, while leveraging digital innovation to enhance the patient experience. As the program gains traction, it has the potential to transform how presbyopia is treated and to set a new standard for patient access in ophthalmology and beyond.
About Tenpoint: Tenpoint Therapeutics Ltd. is an ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.1,2 By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. For more information, visit tenpointtherapeutics.com.
About PHIL Inc.: PHIL is a healthcare technology platform that partners with pharmaceutical manufacturers to empower patients with more convenient and affordable access to their prescribed medications. Through PHIL’s digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale.
Source Link:https://www.businesswire.com/
